Epidermal growth factor receptor function in the human urothelium.

Area of Science:

• Urothelial biology
• Cancer research
• Cell signaling

Background:

• Epidermal growth factor receptor (EGFr) targeted therapy is a potential treatment for urinary bladder cancer.
• Understanding EGFr's role in normal and malignant urothelium is crucial for developing effective therapies.

Purpose of the Study:

• To investigate the role of EGFr in urothelial cell proliferation and migration.
• To evaluate the effects of EGFr inhibition on normal (UROtsa) and malignant (T24) urothelial cells in 2D and 3D culture systems.

Main Methods:

• Cultured normal (UROtsa) and malignant (T24) urothelial cells in collagen gel.
• Assessed proliferation and migration with and without the EGFr inhibitor cetuximab.
• Analyzed expression of key proteins including cytokeratins, EGFr, and tight junction proteins using immunohistochemistry and western blot.

Main Results:

• Cetuximab inhibited proliferation and induced EGFr cleavage in both UROtsa and T24 cells.
• Urothelial migration was not affected by cetuximab treatment.
• Cetuximab treatment cleaved occludin and inhibited spheroid formation in UROtsa cells.

Conclusions:

• EGFr signaling modulates urothelial proliferation and 3D structure formation, potentially via interaction with occludin.
• A novel cell culture technique was established to differentiate normal urothelial cells into epithelial structures, unlike malignant cells.